AlenCiken

Strongly Positive Histological Data

NASDAQ:AKRO   Akero Therapeutics, Inc
Akero Announces Strongly Positive Histological Data Across All Efruxifermin Dose Groups in 16-Week Phase 2a BALANCED Study in NASH Patients

48% fibrosis improvement of at least one stage without worsening of NAS across all dose groups, with a 62% response rate for the 50mg dose group

28% fibrosis improvement of at least two stages across all dose groups, with a 38% response rate for the 50mg dose group

48% NASH resolution without worsening of fibrosis across all dose groups, with a 54% response rate for the 50mg dose group

https://ir.akerotx.com/news-releases/new...

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.